News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,460 Results
Type
Article (41914)
Company Profile (333)
Press Release (665213)
Section
Business (210164)
Career Advice (2080)
Deals (36582)
Drug Delivery (100)
Drug Development (82852)
Employer Resources (171)
FDA (16490)
Job Trends (15360)
News (355490)
Policy (33832)
Tag
Academia (2574)
Alliances (51184)
Alzheimer's disease (1275)
Approvals (16440)
Artificial intelligence (157)
Bankruptcy (362)
Best Places to Work (11715)
Biotechnology (215)
Breast cancer (191)
Cancer (1390)
Cardiovascular disease (116)
Career advice (1741)
Cell therapy (285)
Clinical research (66236)
Collaboration (495)
Compensation (263)
COVID-19 (2612)
C-suite (110)
Data (1400)
Diabetes (174)
Diagnostics (6255)
Earnings (86577)
Employer resources (149)
Events (112864)
Executive appointments (402)
FDA (17171)
Funding (432)
Gene therapy (206)
GLP-1 (631)
Government (4453)
Healthcare (18875)
Infectious disease (2704)
Inflammatory bowel disease (115)
Interviews (320)
IPO (16616)
Job creations (4052)
Job search strategy (1488)
Layoffs (439)
Legal (8326)
Lung cancer (199)
Lymphoma (100)
Manufacturing (215)
Medical device (13297)
Medtech (13302)
Mergers & acquisitions (20117)
Metabolic disorders (470)
Neuroscience (1606)
NextGen Class of 2024 (6625)
Non-profit (4515)
Northern California (1701)
Obesity (268)
Opinion (207)
Patents (120)
People (58416)
Phase I (20512)
Phase II (29147)
Phase III (21855)
Pipeline (517)
Postmarket research (2651)
Preclinical (8730)
Radiopharmaceuticals (241)
Rare diseases (271)
Real estate (6240)
Regulatory (22510)
Research institute (2359)
Resumes & cover letters (358)
Southern California (1468)
Startups (3712)
United States (15332)
Vaccines (582)
Weight loss (196)
Date
Last 7 days (590)
Last 30 days (2325)
Last 365 days (35716)
2024 (35554)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54794)
2019 (47400)
2018 (35771)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (202)
Asia (40138)
Australia (6423)
California (3836)
Canada (1455)
China (311)
Colorado (174)
Connecticut (179)
Europe (85478)
Florida (535)
Georgia (135)
Illinois (394)
Indiana (232)
Maryland (633)
Massachusetts (3007)
Michigan (174)
Minnesota (291)
New Jersey (1117)
New York (1086)
North Carolina (760)
Northern California (1701)
Ohio (146)
Pennsylvania (929)
South America (1157)
Southern California (1468)
Texas (557)
Utah (109)
Washington State (406)
707,460 Results for "cyclacel pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Cyclacel Pharmaceuticals, Inc. announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor.
June 26, 2024
·
5 min read
Business
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday, May 14, 2024.
May 8, 2024
·
3 min read
Drug Development
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company’s cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC).
June 4, 2024
·
7 min read
Press Releases
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
December 6, 2024
·
4 min read
Business
Cyclacel Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced first quarter financial results and provided a business update.
May 14, 2024
·
8 min read
Press Releases
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
November 14, 2024
·
5 min read
Press Releases
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 12, 2024
·
7 min read
Press Releases
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
November 15, 2024
·
4 min read
Business
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.
March 13, 2024
·
3 min read
Business
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.
March 19, 2024
·
9 min read
1 of 70,746
Next
